Search interest in 'GLP-1 and cancer' is surging in 2026 — and the reason is surprising. Emerging research suggests these medications may reduce the risk of obesity-related cancers, not increase it. Here's an honest, sourced breakdown of what's known, what's not, and what the current evidence actually supports.
Obesity is one of the most significant modifiable risk factors for multiple cancer types. The American Cancer Society estimates obesity is linked to approximately 13 types of cancer — including colorectal, endometrial, kidney, liver, pancreatic, esophageal, and breast (postmenopausal) cancers. The biological mechanisms are well-established: excess adipose tissue promotes chronic inflammation, elevates insulin and IGF-1 (growth factors that can drive cell proliferation), and disrupts hormone levels in ways that increase cancer-relevant biological signaling.
If GLP-1 medications produce significant, sustained weight loss — and the trial data confirms they do, at 15-22%+ of body weight — the logical hypothesis is that they might reduce obesity-related cancer risk. The emerging 2026 research is beginning to bear this out.
A study published in JAMA Network Open in 2024, analyzing data from over 60,000 patients with type 2 diabetes, found that semaglutide users had a significantly lower risk of several obesity-related cancers compared to patients on other diabetes medications. The analysis found reduced risk signals for colorectal cancer, kidney cancer, pancreatic cancer, esophageal cancer, endometrial cancer, and ovarian cancer, among others. The risk reduction for the highest-signal cancers ranged from roughly 20-44% compared to the non-GLP-1 comparison group.
The SELECT cardiovascular outcomes trial — which enrolled 17,604 adults with obesity and established cardiovascular disease on semaglutide versus placebo — also tracked cancer-related events as a secondary outcome. Early analysis suggested a favorable signal on cancer-related mortality, though the trial was not powered specifically to evaluate cancer outcomes.
Not all the cancer-related news is positive. GLP-1 medications carry an FDA boxed warning regarding a potential increased risk of medullary thyroid carcinoma (MTC), based on findings from rodent studies. The relevance to humans remains debated — human thyroid tissue expresses GLP-1 receptors at much lower levels than rodent tissue — but the warning is taken seriously and GLP-1 medications are contraindicated in anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Separately, a population-level study examining GLP-1 use and thyroid cancer risk found mixed results, with some analyses showing no increased risk and others showing a modest signal requiring further study. This is an area of active monitoring.
For the obesity-related cancers where excess body weight is a known risk factor, the emerging evidence increasingly suggests GLP-1 medications may provide a protective effect — through weight loss, insulin reduction, and potentially direct anti-inflammatory and anti-proliferative mechanisms. This is a significant, plausible, and increasingly supported finding.
For thyroid cancers specifically (MTC), the boxed warning in the prescribing information should be taken seriously, and anyone with a relevant personal or family history should discuss this explicitly with their physician before starting a GLP-1 medication.
The research is progressing rapidly. Dedicated cancer outcome trials are underway. The current signal is genuinely interesting and largely positive for obesity-related cancers — but the field is not yet at the level of certainty where GLP-1 medications would be recommended specifically for cancer prevention independent of their weight loss and metabolic effects.
DirectMeds offers physician-supervised compounded semaglutide and tirzepatide. Free eligibility check, physician review included.
Check eligibility at DirectMeds →